Genmab Stock Nasdaq Copenhagen
Stocks
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 115B 17.79B 15.41B 14.33B 13.22B 25.01B 1,696B 25.24B 169B 66.23B 846B 66.81B 65.34B 2,804B | P/E 2026 * |
24.5x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 135B 20.78B 18B 16.74B 15.45B 29.21B 1,982B 29.48B 197B 77.38B 989B 78.05B 76.33B 3,276B | EV / Sales 2026 * |
4.77x | EV / Sales 2027 * | 3.83x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab
| 1 day | -0.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.33% | +4.14% | - | - | 17.44B | |
| +10.00% | +13.39% | +51.99% | +83.45% | 56.7B | |
| +0.80% | -7.82% | +24.61% | +60.00% | 51.97B | |
| -0.98% | +0.29% | -14.90% | -14.35% | 23.33B | |
| +0.30% | -5.71% | -9.15% | +345.82% | 21.34B | |
| +4.29% | +1.67% | +201.24% | +344.48% | 14.77B | |
| +1.71% | +0.34% | +50.30% | +169.75% | 13.84B | |
| +4.16% | +4.75% | +462.40% | +177.20% | 12.12B | |
| +5.30% | -7.93% | +67.97% | +162.62% | 11.14B | |
| +2.83% | -2.49% | +114.25% | +147.98% | 10.38B | |
| Average | +2.81% | -0.84% | +105.41% | +164.11% | 23.95B | |
| Weighted average by Cap. | +3.49% | +0.47% | +69.11% | +129.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.25B 4.36B 3.78B 3.51B 3.24B 6.13B 416B 6.18B 41.41B 16.23B 207B 16.37B 16.01B 687B | 33.18B 5.12B 4.43B 4.12B 3.81B 7.2B 488B 7.26B 48.63B 19.06B 244B 19.22B 18.8B 807B |
| Net income | 4.82B 743M 644M 598M 552M 1.04B 70.85B 1.05B 7.06B 2.77B 35.34B 2.79B 2.73B 117B | 7.05B 1.09B 943M 877M 809M 1.53B 104B 1.54B 10.34B 4.05B 51.77B 4.09B 4B 172B |
| Net Debt | 19.4B 2.99B 2.59B 2.41B 2.23B 4.21B 285B 4.25B 28.44B 11.15B 142B 11.24B 10.99B 472B | 11.82B 1.82B 1.58B 1.47B 1.36B 2.56B 174B 2.59B 17.32B 6.79B 86.74B 6.85B 6.7B 287B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
